氨氯地平阿托伐他汀钙片治疗老年高血压、冠心病合并颈动脉粥样硬化患者的疗效

Amlodipine Besylate Atorvastatin Calcium Tablets in the Treatment of Elderly Patients with Hypertension, Coronary Heart Disease and Carotid Atherosclerosis

目的研究氨氯地平阿托伐他汀钙片治疗老年高血压、冠心病合并颈动脉粥样硬化患者的效果。方法抽取该院2018年1月—2019年3月进行治疗的80例老年高血压、冠心病合并颈动脉粥样硬化患者,根据治疗差异分为两组均40例,其中对照组实施氨氯地平治疗,研究组再此基础上实施阿托伐他汀钙片,对比两组患者颈动脉粥样硬化情况、血压、炎症因子。结果治疗前两组患者颈动脉粥样硬化斑块相关数据无明显区别,治疗前两组患者炎症因子,治疗前两组患者的血压无明显变化(P>0.05);治疗后研究组Crouse积分(4.11±1.69)分、IMT(0.80±0.09)mm、斑块面积(13.12±0.89)mm^2、CCAD(5.38±0.16)mm均低于对照组(5.43±2.32)分、(0.89±0.11)min、(14.43±1.05)mm^2、(4.35±0.25)min(t=2.909、4.005、6.019、-21.947,P=0.005、0.000、0.000、0.000);治疗后研究组炎症因子TNF-α(156.52±11.12)ng/L、IL-6(15.52±3.25)ng/L、CRP(3.98±0.88)mg/L低于对照组(209.52±12.54)ng/L、(19.47±3.41)ng/L(7.62±1.25)mg/L(t=20.000、5.303、15.060,P=0.000、0.000、0.000);治疗后研究组舒张压(72.43±7.25)mmHg、收缩压(122.43±10.32)mmHg低于对照组(88.23±9.52)mmHg、(145.34±13.11)mmHg(t=8.351、8.684,P=0.000、0.000),差异无统计学意义(P<0.05)。结论对于高血压、冠心病合并动脉粥样硬化的老年患者,可及时采取氨氯地平阿托伐他汀钙片治疗,患者血压可及时减低,并改善相关炎症因子,且颈动脉粥样硬化斑块情况有效好转,值得应用。

Objective To study the efficacy of Amlodipine Besylate /Atorvastatin Calcium in elderly hypertension and coronary heart disease (CHD) patients with carotid atherosclerosis. Methods A total of 80 elderly hypertension and CHD patients with carotid atherosclerosis treated from January 2018 to March 2019 in our hospital were selected. They were divided into control group (n=40) and study group (n=40) according to different therapies. The control group was treated with Amlodipine Besylate;the study group was treated with Amlodipine Besylate /Atorvastatin Calcium. The atherosclerosis conditions, blood pressure and inflammatory factors were compared. Results Before treatment, related parameters of carotid atherosclerosis plaque between groups were not significantly different. The difference of inflammatory factors between groups were not significantly different. Blood pressure between groups were not significantly different . After treatment, crouse scores, IMT (inteima-media thickness), plaque area and CCAD (common carotid artery diameter) in the study group were (4.11±1.69)points,(0.80±0.09)mm,(13.12±0.89)mm^2 and (5.38±0.16)mm, which were lower than those in the control group [(5.43±2.32)points,(0.89±0.11)mm,(14.43±1.05)mm^2,(4.35±0.25)mm](t=2.909, 4.005, 6.019,-21.947;P=0.005, 0.000, 0.000, 0.000). After treatment, TNF-α(tumor necrosis factor-α), IL-6 (interleukin-6) and CRP (C-reactive protein) contents in the study group were (156.52±11.12)ng/L,(15.52±3.25)ng/L and (3.98±0.88)mg/L, which were lower than those in the control group [(209.52±12.54)ng/L,(19.47±3.41)ng/L,(7.62±1.25)mg/L](t=20.000, 5.303, 15.060;P=0.000, 0.000, 0.000). DBP (diastolic blood pressure) and SBP (systolic blood pressure) in the study group were (72.43±7.25)mmHg and (122.43±10.32)mmHg, which were lower than those in the control group [(88.23±9.52)mmHg,(145.34±13.11)mmHg,(t=8.351, 8.684;P=0.000, 0.000). Conclusion Amlodipine Besylate/Atorvastatin Calcium can properly reduce the blood pressure, and improve relevant inflammatory factors and carotid atherosclerosis plaque conditions. It is worthy of clinical application.